HUYA Bioscience International Sponsors ‘Best New Drug’ Category at SCRIP Awards

« Return

Supports Prestigious Award Recognizing Excellence in Pharmaceutical Development

San Diego, CA, USA – December 3, 2015HUYA Bioscience International (HUYA) was a proud sponsor of the ‘Best New Drug’ category at the 11th Annual SCRIP Awards. Dr. Mireille Gillings was a finalist for ‘Executive of the Year’ and HUYA was a finalist for ‘Best Company in an Emerging Market’. These prestigious awards recognize excellence in the biopharmaceutical industry. HUYA CEO and Executive Chairman, Dr. Mireille Gillings, presented HUYA Bioscience’s Best New Drug Award to Novartis which was recognized for the launch of its new product Cosentyx (secukinumab), a therapy for psoriasis. The award was presented at a ceremony at the Grosvenor House Hotel in London, attended by over 300 industry leaders.


Novartis New Drug Pic_120215

“Congratulations to Novartis on this recognition of excellence in pharmaceutical development,” said Dr. Mireille Gillings, CEO of HUYA. “As we at HUYA are fully aware, launching innovative new products is the most important function of the industry. We are witnessing an exciting new era of drug development based on our ever deeper understanding of molecular medicine. This is generating improved pharmaceuticals with better safety and efficacy through molecular targeting. The next generation of therapies are going to have an enormous impact on public health, increased longevity and enhanced quality of life.”

In this category, the judges were looking for the small-molecule or biological product that was approved in its first market worldwide during the qualifying period that represents the best therapeutic advance in its area. The recipient was selected by an 11-member, independent judging panel of senior industry experts from around the world.

In the 10 years since it was founded, HUYA has advanced the global development of novel oncology and cardiovascular drugs licensed from China. The company was the first to leverage the Tripartite Cooperation between China, Japan and South Korea to use clinical data from China to initiate drug development for HUYA’s lead drug HBI-8000 in Japan for lymphoma. HUYA’s drug has immunomodulatory properties which are important to the clinical development of immuno-oncology therapeutics.

About HUYA Bioscience International

HUYA is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. Extensive collaborations are established with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the U.S., Japan, South Korea and eight strategic locations across China. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally. HUYA was awarded the Asia-Pacific Stevie® Award in the Health Products and Services & Pharmaceuticals category and a Gold Stevie Award in the Woman of the Year 2015 American Business Award category. For more information, please visit

About the SCRIP Awards
The SCRIP Awards provide the industry with an opportunity to acknowledge and applaud its highest achievers across all parts of the value chain, and to recognize both corporate and individual achievement.


Contact Details:

Yiota Merianos
HUYA Corporate Communications